Heart surgery drug showdown: can vasopressin save more kidneys?

NCT ID NCT05568160

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares vasopressin to the standard drug noradrenaline for managing blood pressure after heart surgery. The goal is to see if vasopressin reduces the number of patients who develop acute kidney failure or die. About 840 adults having scheduled heart surgery with a heart-lung machine will participate, and they will be randomly assigned to receive one of the two drugs.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Vasopressin

What this could lead to

If vasopressin works better than noradrenaline, it could become a new standard to prevent kidney failure and reduce deaths after heart surgery.

What could go wrong

This is a large phase 3 trial, but results may not show a clear benefit over the current drug. Kidney protection is complex, and individual responses vary.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for VASOPLEGIC SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Vasoplegia acute kidney injury prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Chu Dijon Bourgogne

    Dijon, France